The aim of this study was to compare the immunogenicity and side-effects of hepatitis A virus (HAV) vaccination between periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) patients and healthy controls who have not been previously exposed to HAV. A prospective observational study was carried out of 28 PFAPA patients and 76 controls who received two doses of the vaccine. Immunogenicity was expressed as seroconversion and seroprotection rates; mean HAV-immunoglobulin G concentration was measured at 0, 1, 7 and 18 months. Side-effects were defined as incidence of adverse events and the effect of vaccination on PFAPA symptoms. All participants were seronegative and seroconverted at 1 month. One month after primary vaccination, 92.9% of PFAPA patients and 77.6% of the controls attained seroprotection, while the rates increased to 100% and 96.1%, respectively, 1 month after the second dose. Seroprotection rates remained adequate 1 year after completion of vaccination. In conclusion, two doses of the inactivated HAV vaccine are well-tolerated and effective in children with PFAPA.
Vaccination in patients with rheumatic disease has been an area of debate given that vaccines may trigger an autoimmune response. 1 Children with autoinflammatory and autoimmune diseases are at increased risk of infection; the recently published European League Against Rheumatism vaccine recommendations for children with rheumatic disease recommend immunization against hepatitis A virus (HAV), 2 but there are no data available to support the tolerability and immunogenicity of the inactivated HAV vaccine in children with periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome.
The aim of this prospective controlled study was to describe the immunogenicity and side-effects of the HAV vaccine in PFAPA patients and to investigate the factors associated with induction of a protective antibody response.
Methods

Patients and setting
The study was conducted between November 2012 and November 2014 at the Second Department of Pediatrics, "P. & A. Kyriakou" Children's Hospital, Athens, Greece. All patients between 2 and 5 years of age diagnosed with PFAPA according to the Marshall criteria were eligible. 3 We excluded patients with acute febrile illness at the time of immunization, disease flare concomitant or up to 3 days prior to vaccination, history of malnutrition, immunodeficiency, blood transfusion or treatment with immunoglobulin or steroids during the preceding 3 months, and those with serological evidence of previous HAV infection or immunization. We also collected demographic data and data concerning disease duration and type of treatment. The control group consisted of healthy children matched for ethnic origin, age and gender to the PFAPA group, attending the Pediatric Outpatients Department for routine school checks; the same exclusion criteria applied.
HAV vaccination
We used a two-dose immunization scheme with a minimum of 6 months between the first and second doses of the inactivated anti-HAV vaccine (Havrix; 0.5 mL = 720 ELISA IU; GlaxoSmith-Kline, Middlesex, UK). The vaccine was given i.m.
Vaccine-induced humoral immunity
Blood samples were obtained for serology at enrollment, 1 month after the first and second dose of the vaccine, and 12 months after the last dose (0, 1, 7, 18 months). Anti-HAV immunoglobulin G (IgG) antibodies were assessed on enzymelinked immunosorbent assay. The cut-offs for seroconversion and seroprotection were 10 and 20 IU/mL, respectively.
Vaccine-induced reactogenicity and tolerability
Adverse events were defined as any adverse change from the baseline condition. We requested families to record any local or systemic symptoms for 7 days after each vaccination. The subjects were actively monitored for disease flare and/or novel autoimmune disease. Onset of typical PFAPA symptoms (fever plus any of pharyngitis, adenitis, mouth ulcers) in ≤1 week after vaccination was defined as a flare. Given that most autoimmune reactions reported by others occurred in ≤3 months following vaccination, 5 we defined this time as the period of vigilant observation for autoimmune reactions.
Ethics and consent
This study was approved by the Hospital's Research and Ethics Committee and was conducted in accordance with the principles of the Declaration of Helsinki and the standards of good clinical practice. Parental written informed consent was also obtained.
Statistical analysis
Demographics and clinical variables, such as gender, race and age, were compared between the two groups. Quantitative variables are expressed as mean AE SD, while qualitative variables are expressed as absolute and relative frequencies. For the comparison of proportions, chi-squared test was used, while t-test was used for the comparison of metric data. All reported P-values are two-tailed. Statistical significance was set at P < 0.05, and analyses were conducted using SPSS version 19.0 (SPSS, Chicago, IL, USA).
Results
Twenty-eight PFAPA patients and 76 controls completed the study; demographic characteristics and time interval between the two vaccine doses were similar in both groups (Table 1) . Thirteen PFAPA patients (46%) received non-steroidal anti-inflammatory drugs (NSAID), nine (32%) received NSAID and corticosteroids, three (10%) received corticosteroids and three (10%) did not receive any treatment at the time of PFAPA flares. Corticosteroids were used on an asneeded basis at the beginning of the PFAPA flare (1-2 mg/ kg prednisolone-single dose). Ibuprofen was the most common NSAID used. All subjects were seronegative at baseline and seroconverted after the scheduled doses. One month after primary vaccination, 92.9% of PFAPA patients and 77.6% of the controls attained seroprotection (P = 0.07), while rates increased to 100% and 96.1% 1 month after the second dose (for the two groups), respectively (P = 0.2). In both groups, seroprotection rates remained elevated 12 months after completion of the study. Seroconversion rates measured at timely intervals were satisfactory for both groups. No statistically significant difference was detected between the two groups.
Mean anti-HAV-IgG concentration at 1 month was 110 mIU/mL in the PFAPA group and 96 mIU/mL in the control group; it reached 223 and 218 mIU/mL after the second dose, respectively, and at 18 months it was 278 mIU/mL in the PFAPA group and 245 mIU/mL in the control group. Mean IgG concentration was not significantly different between the PFAPA and control groups at 1 (P = 0.3), 7 (P = 0.8) and 18 months (P = 0.2). The PFAPA group had persistently raised anti-HAV-IgG antibodies after 18 months. In fact, the PFAPA patients had a better immune response at all time points compared with their healthy counterparts.
On subgroup analysis of the PFAPA group, the use of corticosteroids or NSAID did not affect seroconversion and seroprotection rates or mean anti-HAV-IgG antibody titers. Seroprotection was 89% in PFAPA patients treated with steroids compared with 92% in patients treated with NSAID, 1 month after the second dose; 98% vs. 100% at 7 months; and 98% vs. 100% at 18 months.
Ethnic origin, gender and disease duration had no impact on seroprotection rate or mean anti-HAV-IgG antibody titer. Overall, vaccines were well tolerated. Three PFAPA patients (14.2%) developed a flare (one after the first dose, two after the second dose). The use of steroids did not seem to affect the development of flare. Mild adverse events (low-grade fever, malaise) were noticed in six PFAPA patients (17%) and in 15 controls (21%; Table 1 ). None of the participants developed an autoimmune disease during the follow-up period.
Discussion
The present study is the first to prospectively investigate the immune response to HAV vaccine in children with PFAPA syndrome. Vaccination against HAV was both highly immunogenic and well tolerated in children with PFAPA. An adequate antibody response was noted 1 month after the first dose of inactivated HAV vaccine in the great majority of participants, and the seroconversion rate was similar to that in the healthy control group at all time points. In healthy adult individuals, a single dose of HAV vaccine renders seroprotection. 6 Accordingly, it is common practice to provide short-term protection for a pending trip by giving only one dose to vaccination-na€ ıve travelers. This would also appear to be a logical approach to the pre-travel care of patients with PFAPA syndrome.
In general, the present results are in line with studies performed in healthy children as well as in children with juvenile idiopathic arthritis (JIA), inflammatory bowel disease and autoinflammatory disorders, on immunosuppressive treatment assessing the immunogenicity and safety of the same vaccine. [6] [7] [8] In the majority of these studies, steroid use seemed to hamper immunogenicity. 9 In the present study, steroid treatment was not found to affect antibody titers, but this could be partly due to occasional rather than continuous steroid use. Additionally, the aforementioned studies referred to children with autoimmune diseases rather than periodic fever syndromes.
Disease flare after immunization has been reported in patients with autoinflammatory disorders such as hyper-IgD 10 and systemic onset JIA. 11 We encountered three episodes of PFAPA in the present cohort, which were managed as a routine crisis. Due to the relatively small number of participants, however, no generalized conclusion can be drawn.
Limitations
This study had some drawbacks. We were unable to perform elaborate studies on B-and T-cell repertoire function or to assess the early post-immunization response by measuring IgM concentration. Due to the small number of participants in the PFAPA cohort, we were underpowered to detect differences between the various treatment regimens. The same applied for the other factors tested.
In conclusion, two doses of the inactivated HAV vaccine were immunogenic and well-tolerated in children with PFAPA. Immunity persisted for at least 12 months following completion of the immunization scheme. A single dose of the vaccine was sufficient to confer adequate seroprotection in 97% of the patients. Vaccination against HAV should be considered in countries where hepatitis A is endemic, Additional studies are needed to assess the long-term response to the HAV vaccine in patients with PFAPA,
